Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/21/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Richard E. Chipkin

Wrong Dr. Richard E. Chipkin?

President and Chief Executive Off...

Phone: (301) ***-****  
Psyadon Pharmaceuticals , Inc.
20451 Seneca Meadows Parkway
Germantown , Maryland 20876
United States

Company Description: Psyadon Pharmaceuticals is dedicated to the discovery and development of new treatments for the serious psychiatric and neurological diseases. Ecopipam, our first...   more

Employment History

Board Memberships and Affiliations


  • undergraduate degree , Pharmacology
    State University of New York at Albany
  • Ph.D. , Pharmacology
    Medical College of Virginia
59 Total References
Web References
Psyadon Pharmaceuticals Home Page, 13 Aug 2015 [cached]
Dr. Richard E. Chipkin, PhD, President and CEO
Dr. Chipkin has more than 20 years experience at both biotech and big pharmaceutical companies. Most recently, he was President and CEO of Psychiatric Genomics. While there, he raised two rounds of venture capital financing, re-organized the company, and negotiated multiple academic licenses. Prior to that, he worked at Schering-Plough Corporation in the Global Business Development Group, where he was responsible for licensing and acquisition in multiple therapeutic areas. In this capacity, Dr. Chipkin negotiated several multi-million dollar research & development and development/marketing deals, including the license for INTEGRILIN®, currently a $250M/year product. Earlier in his career at Schering-Plough, he held positions in both preclinical and clinical neuropharmacology research. Among his accomplishments in the research arena were the discovery of novel analgesic and antipsychotic drugs, including the identification and human testing of ecopipam -- the world's first selective D1 antagonist. Dr. Chipkin received his undergraduate degree from the State University of New York at Albany and his PhD in Pharmacology from the Medical College of Virginia. He did post-doctoral work at the University of Colorado Medical Center.
Board of Directors | Tech Council of Maryland, 9 Aug 2015 [cached]
Richard E. Chipkin, Ph.D. President and Chief Executive Officer Psyadon Pharmaceuticals
University of Maryland BioPark, 4 Jan 2015 [cached]
Richard E. Chipkin, Ph.D., President and CEO, Psyadon Pharmaceuticals
Ruxton Pharmaceuticals, Inc., 22 Oct 2009 [cached]
Richard E. Chipkin, PhD President and C.E.O., Ruxton Pharmaceuticals, Inc.
The Business Gazette: Biotech raises $17M, starts looking for more, 22 Nov 2002 [cached]
Psychiatric Genomics Inc., which develops drugs to treat mental health disorders, looks to close its second round of funding with $25 million to $30 million, said Richard Chipkin, the company's CEO.
The money will be used to develop drugs to fight diseases such as bipolar disorder, schizophrenia, depression and autism, he said.
The company hopes to have drug targets in clinical trials in the first half of 2004, Chipkin said by telephone Wednesday from Psychiatric Genomics' headquarters at 19 Firstfield Road.
The privately held biotech company, with a work force of 40, is developing products using genomics-based technology to screen for multiple drug targets rather than just one, he said.
"We think the genomics approach will increase effectiveness and [decrease] side effects," Chipkin said.Each of these drug candidates has a multibillion-dollar market, he said.
A medicine to combat schizophrenia developed by pharmaceutical giant Eli Lilly & Co., for example, will likely have sales of between $2.5 billion and $3 billion this year, Chipkin said.
The money Psychiatric Genomics has raised is expected to last the company until the next initial public offering window, which could be as far off as 2005 or 2006, said Chipkin, a Schering-Plough Corp. executive of 20 years who came aboard as the company's chief executive in August 2001.
Psychiatric Genomics, founded in January 2000, raised $12 million in its first round of venture capital financing, he said.Investors in its two rounds include Alexandria Real Estate Equities Inc., which is based in Pasadena, Calif., and has a Rockville office; Catalytix LDC of the Cayman Islands; Emerging Technology Partners LLC of Rockville; the Maryland Department of Business and Economic Development; Oxford Bioscience Partners of Boston; and the Stanley Medical Research Institute in Bethesda.
Funding in biotech companies is down for the year when compared with 2001, a survey by the Mid-Atlantic Venture Association said, and the biotech sector is below other high-tech industries, such as software, Internet and telecommunications, in terms of investor demand.
Venture capitalists have become reluctant to invest in early and middle-stage drug developers, in particular, because they typically need several years and hundreds of millions of dollars to bring their products to market.
The Bethesda research institute is providing tissue samples to Psychiatric Genomics from patients suffering from bipolar disorder, schizophrenia and depression to help the biotech company in its research and development efforts, Chipkin said.
Psychiatric Genomics has 12,500 square feet of office and laboratory space in Gaithersburg, Chipkin said, but it will grow to 25,000 square feet when Avalon relocates to Germantown in the first quarter 2003.
Psychiatric Genomics will increase its work force, though Chipkin could not provide specifics, saying the company's expansion will depend on research and development partnerships it makes with global biotech and pharmaceutical companies. * *
Return to top
> >
> Copyright © 2002 Gazette Newspapers - ALL RIGHTS RESERVED.
Other People with the name "Chipkin":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.